Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Clinical safety

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In contrast, patients with LB pathology alone, in the absence of AD biomarker positivity, had less overall cognitive impairment but more focal dysexecutive and visuospatial deficits. So, the presence of LB co-pathology was associated with more aggressive disease but did not always lead to DLB-like clinical features. This effect of co-pathologies altering the disease course is also seen in patients diagnosed with DLB, and the related condition PD dementia, where AD co-pathology is associated with more rapid progression, poorer cognition5 and earlier age of onset. For example, cerebral amyloid angiopathy correlates with AD co-pathology2 and is increased in DLB and Parkinson’s dementia compared with PD8; and TDP-43 co-pathology is increased in patients with AD and is associated with poorer cognition.9 Silva-Rodríguez and colleagues3 also examined regional variation in hypometabolism using FDG-PET and showed that AD patients had a typical AD-like pattern of temporo-parietal hypometabolism, regardless of the presence or absence of LB co-pathology, reflecting the clinical presentation. For example, Duong et al.10 recently showed that patients in the same ADNI cohort with beta-amyloid and alpha-synuclein positivity have reduced posterior parieto-occipital reduced glucose metabolism but relative sparing of cortical atrophy.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 85 participants. This paper discusses how co-pathologies such as Lewy body and TDP-43 pathology alter the disease course in Alzheimer's disease and dementia with Lewy bodies, being associated with more aggressive disease and poorer cognition. Reported effect size: 97.8%; 98.1%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Weil, R. S. (2025). Seeing the trees in the wood: the importance of co-pathologies in Alzheimer’s disease and dementia with Lewy bodies. Brain. https://doi.org/10.1093/brain/awaf197

Vancouver

Weil RS. Seeing the trees in the wood: the importance of co-pathologies in Alzheimer’s disease and dementia with Lewy bodies. Brain. 2025. doi:10.1093/brain/awaf197. PMID: 40623303.

BibTeX

@article{weil2025-40623303,
  author  = {Weil, Rimona Sharon},
  title   = {{Seeing the trees in the wood: the importance of co-pathologies in Alzheimer’s disease and dementia with Lewy bodies}},
  journal = {Brain},
  year    = {2025},
  doi     = {10.1093/brain/awaf197},
  pmid    = {40623303},
  url     = {https://doi.org/10.1093/brain/awaf197}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This paper discusses how co-pathologies such as Lewy body and TDP-43 pathology alter the disease course in Alzheimer's disease and dementia with Lewy bodies, being associated with more aggressive disease and poorer cognition. It describes the importance of co-pathologies for understanding disease progression but does not test any treatment, cure or prevention.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 53 of 100.53 of 100 points earned47 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Brain)
Journal's citation record 4 / 4 Brain: journal h-index 503 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 85 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Rimona Sharon Weil: h-index 39 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40623303)
Free to read 2 / 2 Free to read
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Clinical safety from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical safety

See all studies in Clinical safety →